Titre : Vincristine

Vincristine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Keratoconus

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment la vincristine est-elle utilisée dans le diagnostic ?

La vincristine n'est pas un outil de diagnostic, mais un traitement pour des cancers diagnostiqués.
Vincristine Cancer Diagnostic
#2

Quels tests précèdent l'administration de vincristine ?

Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie.
Tests de laboratoire Imagerie médicale Vincristine

Symptômes 2

#1

Quels sont les effets secondaires de la vincristine ?

Les effets secondaires incluent neuropathie, constipation, et fatigue.
Effets secondaires Neuropathie Vincristine
#2

La vincristine cause-t-elle des douleurs ?

Oui, elle peut provoquer des douleurs neuropathiques chez certains patients.
Douleur Neuropathie Vincristine

Prévention 2

#1

Peut-on prévenir les effets secondaires de la vincristine ?

Des mesures préventives incluent une surveillance étroite et des médicaments pour les symptômes.
Prévention Effets secondaires Vincristine
#2

Y a-t-il des recommandations avant le traitement par vincristine ?

Oui, une évaluation médicale complète est recommandée avant le traitement.
Évaluation médicale Vincristine Préparation au traitement

Traitements 2

#1

Avec quels médicaments la vincristine est-elle souvent combinée ?

Elle est souvent combinée avec la prednisone et d'autres agents chimiothérapeutiques.
Chimiothérapie Vincristine Prednisone
#2

Comment la vincristine est-elle administrée ?

La vincristine est administrée par voie intraveineuse, généralement en cycle.
Administration intraveineuse Vincristine Chimiothérapie

Complications 2

#1

Quelles complications peuvent survenir avec la vincristine ?

Des complications incluent des infections, des troubles neurologiques et des problèmes gastro-intestinaux.
Complications Infections Vincristine
#2

La vincristine peut-elle causer des problèmes cardiaques ?

Bien que rare, des problèmes cardiaques peuvent survenir, nécessitant une surveillance.
Problèmes cardiaques Vincristine Surveillance médicale

Facteurs de risque 2

#1

Qui est à risque d'effets indésirables de la vincristine ?

Les patients âgés et ceux avec des antécédents de neuropathie sont à risque accru.
Facteurs de risque Neuropathie Vincristine
#2

Les antécédents médicaux influencent-ils le traitement par vincristine ?

Oui, des antécédents de maladies neurologiques peuvent affecter le traitement.
Antécédents médicaux Vincristine Neurologie
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vincristine : Questions médicales les plus fréquentes", "headline": "Vincristine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vincristine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-27", "dateModified": "2025-02-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vincristine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alcaloïdes de Vinca", "url": "https://questionsmedicales.fr/mesh/D014748", "about": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca", "code": { "@type": "MedicalCode", "code": "D014748", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827" } } }, "about": { "@type": "MedicalCondition", "name": "Vincristine", "alternateName": "Vincristine", "code": { "@type": "MedicalCode", "code": "D014750", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wenjian Yang", "url": "https://questionsmedicales.fr/author/Wenjian%20Yang", "affiliation": { "@type": "Organization", "name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Deqing Pei", "url": "https://questionsmedicales.fr/author/Deqing%20Pei", "affiliation": { "@type": "Organization", "name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Cheng Cheng", "url": "https://questionsmedicales.fr/author/Cheng%20Cheng", "affiliation": { "@type": "Organization", "name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "William E Evans", "url": "https://questionsmedicales.fr/author/William%20E%20Evans", "affiliation": { "@type": "Organization", "name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Richard H Ho", "url": "https://questionsmedicales.fr/author/Richard%20H%20Ho", "affiliation": { "@type": "Organization", "name": "Vanderbilt University Medical Center, Nashville, TN." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Keratoconus.", "datePublished": "2024-10-24", "url": "https://questionsmedicales.fr/article/39448666", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41572-024-00565-3" } }, { "@type": "ScholarlyArticle", "name": "Keratoconus International Consortium (KIC)- advancing keratoconus research.", "datePublished": "2023-07-27", "url": "https://questionsmedicales.fr/article/37501133", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12886-023-03087-w" } }, { "@type": "ScholarlyArticle", "name": "Biomechanical properties analysis of forme fruste keratoconus and subclinical keratoconus.", "datePublished": "2022-11-28", "url": "https://questionsmedicales.fr/article/36441226", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00417-022-05916-y" } }, { "@type": "ScholarlyArticle", "name": "Recurrent Keratoconus: Corneal Transplants for Keratoconus Develop Tomographic Ectatic Changes.", "datePublished": "2022-11-21", "url": "https://questionsmedicales.fr/article/36730373", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/ICO.0000000000003149" } }, { "@type": "ScholarlyArticle", "name": "Comparison of a Scheimpflug imaging with other screening indices in diagnosing keratoconus and keratoconus suspect.", "datePublished": "2024-10-05", "url": "https://questionsmedicales.fr/article/39369097", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-74497-z" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indolizine", "item": "https://questionsmedicales.fr/mesh/D007212" }, { "@type": "ListItem", "position": 6, "name": "Indolizidines", "item": "https://questionsmedicales.fr/mesh/D054836" }, { "@type": "ListItem", "position": 7, "name": "Alcaloïdes indoliques", "item": "https://questionsmedicales.fr/mesh/D026121" }, { "@type": "ListItem", "position": 8, "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "item": "https://questionsmedicales.fr/mesh/D046948" }, { "@type": "ListItem", "position": 9, "name": "Alcaloïdes de Vinca", "item": "https://questionsmedicales.fr/mesh/D014748" }, { "@type": "ListItem", "position": 10, "name": "Vincristine", "item": "https://questionsmedicales.fr/mesh/D014750" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vincristine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vincristine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-06", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vincristine", "description": "Comment la vincristine est-elle utilisée dans le diagnostic ?\nQuels tests précèdent l'administration de vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Keratoconus#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vincristine", "description": "Quels sont les effets secondaires de la vincristine ?\nLa vincristine cause-t-elle des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Keratoconus#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vincristine", "description": "Peut-on prévenir les effets secondaires de la vincristine ?\nY a-t-il des recommandations avant le traitement par vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Keratoconus#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vincristine", "description": "Avec quels médicaments la vincristine est-elle souvent combinée ?\nComment la vincristine est-elle administrée ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Keratoconus#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vincristine", "description": "Quelles complications peuvent survenir avec la vincristine ?\nLa vincristine peut-elle causer des problèmes cardiaques ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Keratoconus#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vincristine", "description": "Qui est à risque d'effets indésirables de la vincristine ?\nLes antécédents médicaux influencent-ils le traitement par vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Keratoconus#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la vincristine est-elle utilisée dans le diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La vincristine n'est pas un outil de diagnostic, mais un traitement pour des cancers diagnostiqués." } }, { "@type": "Question", "name": "Quels tests précèdent l'administration de vincristine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie." } }, { "@type": "Question", "name": "Quels sont les effets secondaires de la vincristine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent neuropathie, constipation, et fatigue." } }, { "@type": "Question", "name": "La vincristine cause-t-elle des douleurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des douleurs neuropathiques chez certains patients." } }, { "@type": "Question", "name": "Peut-on prévenir les effets secondaires de la vincristine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures préventives incluent une surveillance étroite et des médicaments pour les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des recommandations avant le traitement par vincristine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une évaluation médicale complète est recommandée avant le traitement." } }, { "@type": "Question", "name": "Avec quels médicaments la vincristine est-elle souvent combinée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle est souvent combinée avec la prednisone et d'autres agents chimiothérapeutiques." } }, { "@type": "Question", "name": "Comment la vincristine est-elle administrée ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La vincristine est administrée par voie intraveineuse, généralement en cycle." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la vincristine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections, des troubles neurologiques et des problèmes gastro-intestinaux." } }, { "@type": "Question", "name": "La vincristine peut-elle causer des problèmes cardiaques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Bien que rare, des problèmes cardiaques peuvent survenir, nécessitant une surveillance." } }, { "@type": "Question", "name": "Qui est à risque d'effets indésirables de la vincristine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les patients âgés et ceux avec des antécédents de neuropathie sont à risque accru." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le traitement par vincristine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies neurologiques peuvent affecter le traitement." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 21/02/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Wenjian Yang

3 publications dans cette catégorie

Affiliations :
  • Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Deqing Pei

3 publications dans cette catégorie

Affiliations :
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Cheng Cheng

3 publications dans cette catégorie

Affiliations :
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

William E Evans

3 publications dans cette catégorie

Affiliations :
  • Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Richard H Ho

3 publications dans cette catégorie

Affiliations :
  • Vanderbilt University Medical Center, Nashville, TN.

Sima Jeha

2 publications dans cette catégorie

Affiliations :
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Ching-Hon Pui

2 publications dans cette catégorie

Affiliations :
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Mirjam E van de Velde

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Aniek Uittenboogaard

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Gertjan J L Kaspers

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.

Esperanza Herradón

2 publications dans cette catégorie

Affiliations :
  • Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
  • Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
  • High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :

Visitación López-Miranda

2 publications dans cette catégorie

Affiliations :
  • Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
  • Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
  • High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :

Yang Li

2 publications dans cette catégorie

Affiliations :
  • Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, PR China.

Jing Huang

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Mental Health Institute of the Second Xiangya Hospital, Central South University, Chinese National Clinical Research Center on Mental Disorders (xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China.
Publications dans "Vincristine" :

Johnny Donovan

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Zicheng Deng

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.
  • Center for Lung Regenerative Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Fenghua Bian

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Samriddhi Shukla

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.

Jose Gomez-Arroyo

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • Division of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States.

Donglu Shi

2 publications dans cette catégorie

Affiliations :
  • The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.

Sources (705 au total)

Keratoconus International Consortium (KIC)- advancing keratoconus research.

The Keratoconus International Consortium (KIC) will allow better understanding of keratoconus.... Keratoconus is a disorder characterised by corneal elevation and thinning, leading to reduced vision. The current gaps in understanding of this disease will be discussed and the need for a multi-prong... KIC has been established to address the gaps in our understanding of keratoconus with the aim of collecting baseline as well as longitudinal data on several fields.... Keratoconus and control (no corneal condition) subjects from different sites globally will be recruited in the study.... KIC collects data using an online, secure database, which enables standardised data collection at member sites. Data fields collected include medical history, clinical features, quality of life and ec... There are currently 40 Australian and international clinics or hospital departments who have joined the KIC. Baseline data has so far been collected on 1130 keratoconus patients and indicates a median... The strength of this consortium is its international, collaborative design and use of a common data collection tool. Inclusion and analyses of cross-sectional and longitudinal data will help answer ma...

Biomechanical properties analysis of forme fruste keratoconus and subclinical keratoconus.

To analyze the biomechanical properties of the eye in patients with unilateral keratoconus with normal (forme fruste keratoconus [FFKC]) or abnormal topography (subclinical keratoconus [SKC]).... This study included 153 eyes of 153 participants, including 95 eyes of patients with unilateral keratoconus, and 58 eyes of 58 healthy controls. Contralateral eyes with unilateral keratoconus were div... Statistically significant differences between the FFKC and SKC groups were found in 9 of the 18 corneal biomechanical parameters analyzed using non-parametric tests. After adjusting for confounding fa... Biomechanical parameters A1-time and IR have a high diversity between FFKC and SKC, besides TBI, and may reflect more subtle changes in corneal biomechanical properties (BPs) preceding SP-A1. The BPs ...

Recurrent Keratoconus: Corneal Transplants for Keratoconus Develop Tomographic Ectatic Changes.

The purpose of this study was to evaluate postoperative Scheimpflug imaging changes during the first 5 years after penetrating keratoplasty (PK) in patients with keratoconus (KC).... This retrospective, interventional case series includes 31 eyes of 31 patients who underwent their first PK with a history of KC. Postoperative Scheimpflug imaging was performed 3 months after the rem... The maximal keratometry (Kmax) progressed significantly between baseline (53.5 ± 6.1 D) and postoperative year 3 and year 5 [56.5 ± 6.1 diopter (D) and 58.8 ± 7.9 D, P < 0.001]. Significant changes we... Tomographic graft changes indicative of ectasia were observed within 3 to 5 years after PK in patients with KC. These changes were observed more frequently and sooner after corneal transplants than pr...

Patient-Reported Outcomes in Keratoconus: A Save Sight Keratoconus Registry Study.

The aim of this study was to evaluate the quality-of-life (QoL) status in keratoconus severity subgroups using the Keratoconus Outcomes Research Questionnaire (KORQ) and to determine the relationship ... A cross-sectional study was conducted using prospective, web-based Save Sight Keratoconus Registry data. Rasch analysis was conducted on the KORQ data using the Andrich Rating Scale Model. Comparative... The KORQ was completed by 542 patients with keratoconus (male, 67.7%; mean age, 31.6 years). Keratoconus severity, based on Kmax, was mild [<48 diopter (D)], moderate (48-55 D), and severe (>55 D) in ... Female sex, contact lens wear, reduced visual acuity, and higher disease severity were associated with worse AL and SY scores in keratoconus. Although the correlations between clinical and QoL scores ...

Revisiting the oil droplet sign in keratoconus: Utility for early keratoconus diagnosis and screening.

An annular dark shadow (ADS) reflex has been observed while performing direct ophthalmoscopy on subjects with keratoconus. This study describes a method that may serve as a diagnostic technique for ea... Healthy keratoconic subjects and keratoconus suspects underwent corneal tomography and a full ocular examination. Keratoconus severity was graded based on Belin ABCD criteria. An iPhone camera was con... Fifty-eight subjects participated in this study: 37 healthy controls (37 eyes) and 21 keratoconics or keratoconus suspects (37 eyes). The ADS was present in all keratoconic and keratoconus-suspect eye... The ADS may be a useful method to diagnose keratoconus and keratoconus-suspect cases and serve as a grading and follow-up method for tracking disease severity....

Keratoconus: A Biomechanical Perspective.

The relevance of corneal biomechanics and the importance of including it in the clinical assessment of corneal ectasias are being increasingly recognized. The connection between corneal ultrastructure... Published articles on corneal biomechanics in the specific context of keratoconus were reviewed, based on an electronic search using PubMed, Elsevier, and Science Direct. The search terms used include... The electronic search revealed more than 500 articles, from which 80 were chosen for this article.... The structural and organizational pattern of the corneal stroma determines its mechanical properties and are responsible for the maintenance of the normal shape and function of the cornea. Changes in ...

Evaluation of Anterior and Posterior Corneal Higher Order Aberrations for the Detection of Keratoconus and Suspect Keratoconus.

To investigate the application of anterior and posterior corneal higher-order aberrations (HOAs) in detecting keratoconus (KC) and suspect keratoconus (SKC).... A retrospective, case-control study evaluating non-ectatic (normal) eyes, SKC eyes, and KC eyes. The Sirius Scheimpfug (CSO, Italy) analyses was used to measure HOAs of the anterior and posterior corn... Two-hundred and twenty eyes were included in the analysis (normal n = 108, SKC n = 42, KC n = 70). Receiver operating characteristic (ROC) curve analysis revealed a high predictive ability for anterio... Anterior and posterior corneal higher-order aberrations can differentiate between keratoconus and normal eyes, with a high level of certainty. In suspect keratoconus disease, however, only anterior co...

Comparison of Keratoconus Specific to Standard IOL Formulas in Patients With Keratoconus Undergoing Cataract Surgery.

To assess the performance of multiple intraocular lens (IOL) formulas in eyes with keratoconus.... Eyes with stable keratoconus scheduled for cataract surgery with biometry measurements on the Lenstar LS900 (Haag-Streit) were included. Prediction errors were calculated using 11 different formulas, ... Sixty-eight eyes from 44 patients were identified. In eyes with keratometric values less than 50.00 D, prediction error standard deviations ranged from 0.680 to 0.857 D. Percentages of eyes within ±0.... In keratoconic eyes, IOL formulas are less accurate than in normal eyes and result in hyperopic refractive outcomes that increase with steeper keratometric values. Using keratoconus-specific formulas ...